PFE - Morgan Stanley sees $180B patent cliff $380B deal capacity fueling biopharma M&A
2024-07-13 14:03:47 ET
More on Amgen, Biogen, etc.
- Biogen's Diverse Drug Portfolio Faces Competitive Challenges In 2024
- Merck: Positive Developments, But Watch The Q2 Earnings
- Biogen Stock: Cheapish, But With Few Growth Prospects
- This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment
- Prelude, Merck strike clinical trial collaboration and supply pact